Form 4 · LLY
Eli Lilly director Gabrielle Sulzberger reports an award of about 171 shares
Part of a grouped insider digest: see all related filings with totals →
Gabrielle Sulzberger, an Eli Lilly director, filed a Form 4 on Nov 17, 2026 at 4:13 PM ET reporting transactions on Nov 16, 2026.
The filing reports about 171 shares in a grant or award (code A).
After these transactions, the filing lists about 3,188 shares held directly.
Effect on holdings
Taken together, the rows reported here raised Gabrielle Sulzberger's directly held shares by 5.7%, from about 3,016 to about 3,188.
Reporting person
- Gabrielle Sulzberger, director (as filed: Sulzberger Gabrielle)
Transactions as reported
| Date | Code | Security | Shares | Price | Acquired or disposed | Held after | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-11-16 | A | Common Stock | 3 | $1,431.67 | Acquired | 3,020 | Direct |
| 2026-11-16 | A | Common Stock | 168 | $1,431.67 | Acquired | 3,188 | Direct |
Codes: P purchase, S sale, A grant or award, M/X/C exercise or conversion, F shares withheld for taxes or the exercise price, G gift. Prices are as reported; some are weighted averages of several trades.
Source
- Form 4 filed Nov 17, 2026 (document)
- Filing index on SEC EDGAR (all documents and exhibits)
Eli Lilly company file → · More Eli Lilly filings
Disclosures
- Editor holdings in LLY
- The editor holds no position in Eli Lilly (LLY). As of Nov 11, 2026.
- Last updated
- Nov 17, 2026
A summary of a public filing for general education, the same for every reader. Not a recommendation to buy, sell or hold LLY.